Rasal1 impairment unleashes anticancer immunity - a focus on T cells

preprint OA: closed
Full text JSON View at publisher

Abstract

ABSTRACT Immune checkpoint blockade (ICB) has demonstrated clinical efficacy in several cancers, including melanoma, lung, colorectal, and liver malignancies. However, a substantial proportion of patients fail to respond, underscoring the need for alternative immunotherapeutic strategies capable of overcoming resistance to conventional checkpoint inhibition. One such strategy involves targeting intracellular inhibitory immune checkpoints that regulate effector lymphocyte function. Rasal1, a Ras GTPase-activating protein, has been shown to negatively regulate T cell-mediated antitumor immunity. In this study, we further characterized the impact of Rasal1 impairment on tumor progression, T cell stemness, and effector function. Using an endonuclease-mediated mutation targeting the C2 domain of Rasal1, we demonstrate that Rasal1-impaired (Rasal1i) mice exhibit significantly reduced tumor growth across multiple murine cancer models. Rasal1i mice displayed increased intratumoral CD8 + T cell accumulation, activation, cytolytic capacity, and enhanced Wnt signaling. Tumor-infiltrating lymphocytes additionally exhibited increased progenitor and stem-like memory phenotypes. Notably, Rasal1 inhibition prolonged survival and potentiated αPD-1 therapy in a resistant PD-L1-expressing B16F10 melanoma model. Collectively, these findings identify Rasal1 as an intracellular inhibitory immune checkpoint that constrains T cell stemness and antitumor function, and support its further evaluation as a therapeutic target for cancer immunotherapy.
Full text 2,746 characters · extracted from oa-doi-fallback · click to expand
ABSTRACT Immune checkpoint blockade (ICB) has demonstrated clinical efficacy in several cancers, including melanoma, lung, colorectal, and liver malignancies. However, a substantial proportion of patients fail to respond, underscoring the need for alternative immunotherapeutic strategies capable of overcoming resistance to conventional checkpoint inhibition. One such strategy involves targeting intracellular inhibitory immune checkpoints that regulate effector lymphocyte function. Rasal1, a Ras GTPase-activating protein, has been shown to negatively regulate T cell-mediated antitumor immunity. In this study, we further characterized the impact of Rasal1 impairment on tumor progression, T cell stemness, and effector function. Using an endonuclease-mediated mutation targeting the C2 domain of Rasal1, we demonstrate that Rasal1-impaired (Rasal1i) mice exhibit significantly reduced tumor growth across multiple murine cancer models. Rasal1i mice displayed increased intratumoral CD8+ T cell accumulation, activation, cytolytic capacity, and enhanced Wnt signaling. Tumor-infiltrating lymphocytes additionally exhibited increased progenitor and stem-like memory phenotypes. Notably, Rasal1 inhibition prolonged survival and potentiated αPD-1 therapy in a resistant PD-L1-expressing B16F10 melanoma model. Collectively, these findings identify Rasal1 as an intracellular inhibitory immune checkpoint that constrains T cell stemness and antitumor function, and support its further evaluation as a therapeutic target for cancer immunotherapy. Competing Interest Statement The authors have declared no competing interest. Abbreviations - AUC - area under the curve - ICB - immune checkpoint blockade - Ras - rat sarcoma - GAP - GTPase-activating protein - RNA-seq - RNA sequencing - DCs - dendritic cells - MAPK - mitogen-activated protein kinase - RAF - rapidly accelerated fibrosarcoma - MEK - MAPK/ERK kinase - ERK - extracellular signal-regulated kinase - GDP - guanosine diphosphate - TCR - T cell receptor - PD-1 - programmed cell death protein 1 - PD-L1 - programmed death-ligand 1 - CD8+ - cluster of differentiation 8-positive - CD4+ - cluster of differentiation 4-positive - TILs - tumor-infiltrating lymphocytes - Ki67 - marker of proliferation Ki-67 - Myc - MYC proto-oncogene - T-SCM - stem-like memory T cells - Wnt - Wingless-related integration site - CLPs - common lymphoid progenitors - LRP5/6 - low-density lipoprotein receptor-related protein 5/6 - APC - adenomatous polyposis coli - CK1 - casein kinase 1 - GSK3 - glycogen synthase kinase 3 - TCF1 - T cell factor 1 - CXCR5 - C-X-C chemokine receptor type 5 - CXCL13 - C-X-C motif chemokine ligand 13 - TCGA - The Cancer Genome Atlas - NSCLC - non-small cell lung cancer.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00